Ernexa Therapeutics Inc. cotiza a 2.21 USD y tiene una capitalización bursátil de $4M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian…
| Periodo | 2026-08 | 2026-05 | 2022-11 | 2022-08 |
|---|---|---|---|---|
| Real | $-3.40 | $-6.95 | $-933.75 | $-450.00 |
| Estimado | $-3.30 | $-1.95 | $-825.00 | $-975.00 |
| Sorpresa | -3.0% | -256.4% | -13.2% | +53.8% |
| Métrica | ERNA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -586.6% | -40.4% | -546.2% |
| ROA | -241.4% | -32.0% | -209.4% |
| Current Ratio | 1.01 | 2.84 | -1.83 |
| Debt / Equity | — | 0.28 | — |